Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)
Close on Nov 17, 2026Market cap $1.69BP/E –Yield –
Earnings
Braveheart Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.51
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Braveheart Bio's earnings releases, newest first
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Braveheart Bio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Braveheart Bio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Braveheart Bio filed with the SEC as exhibits to Form 8-K or 6-K
See a number that looks wrong?